Insider · CIK 0001532830

Glasheen James Walter

Reports to the SEC for 2 companies · MILL VALLEY, CA

sec.gov

Transactions

Companies

Filings

CIK

0001532830

Forms 4 and 5

Insider transactions

26 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-06-11	SOLENO THERAPEUTICS INCEmployee stock option (right to buy)A Award	Director	AAward	+15.9K sh	—	—	15,931
2018-02-05	SOLENO THERAPEUTICS INCA Award	Director	AAward	+3,962 sh	$1.73	+$6,839.601	1,419,489
2017-10-02	SOLENO THERAPEUTICS INCA Award	Director	AAward	+13.2K sh	$0.52	+$6,840.08	26,945
2017-07-06	SOLENO THERAPEUTICS INCA Award	Director	AAward	+11.2K sh	$0.61	+$6,839.93	13,791
2017-05-08	SOLENO THERAPEUTICS INCEmployee stock option (right to buy)A Award	Director	AAward	+45.1K sh	—	—	45,139
2017-04-07	SOLENO THERAPEUTICS INCA Award	Director	AAward	+2,578 sh	$0.63	+$1,624.14	2,578
2017-03-07	SOLENO THERAPEUTICS INCEmployee stock option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2016-05-05	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,000 sh	—	—	8,000
2015-05-07	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,000 sh	—	—	8,000
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director	CConversion	+16.7K sh	—	—	16,703
2014-02-11	Revance Therapeutics, Inc.X Exercise of In-Money	Director	XExercise of In-Money	+149 sh	—	—	16,852
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director	CConversion	+623K sh	—	—	622,648
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director	CConversion	+34.4K sh	—	—	657,075
2014-02-11	Revance Therapeutics, Inc.X Exercise of In-Money	Director	XExercise of In-Money	+52.1K sh	—	—	709,162
2014-02-11	Revance Therapeutics, Inc.Series E-1 Convertible Preferred StockC Conversion	Director	CConversion	−5,231 sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-1 Convertible Preferred StockC Conversion	Director	CConversion	−82K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-2 Convertible Preferred StockC Conversion	Director	CConversion	−4,125 sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-2 Convertible Preferred StockC Conversion	Director	CConversion	−73.3K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-3 Convertible Preferred StockC Conversion	Director	CConversion	−4,546 sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-3 Convertible Preferred StockC Conversion	Director	CConversion	−74.7K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-4 Convertible Preferred StockC Conversion	Director	CConversion	−2,801 sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-4 Convertible Preferred StockC Conversion	Director	CConversion	−304K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-5 Convertible Preferred StockC Conversion	Director	CConversion	−89.2K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Convertible Promissory NotesC Conversion	Director	CConversion	−34.4K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Warrant to Purchase Common StockX Exercise of In-Money	Director	XExercise of In-Money	−149 sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Warrant to Purchase Common StockX Exercise of In-Money	Director	XExercise of In-Money	−52.1K sh	—	—	0

Recent filings

Accepted (ET)
Jun 184
Glasheen James Walter0000899243-18-017059
SEC(opens sec.gov)
Feb 74
Glasheen James Walter0000899243-18-003157
SEC(opens sec.gov)
Oct 44
Glasheen James Walter0000899243-17-023581
SEC(opens sec.gov)
Jul 174
Glasheen James Walter0000899243-17-018364
SEC(opens sec.gov)
May 94
Capnia, Inc.0000899243-17-012474
SEC(opens sec.gov)
Apr 134
Capnia, Inc.0000899243-17-010283
SEC(opens sec.gov)
Mar 104
Capnia, Inc.0000899243-17-007148
SEC(opens sec.gov)
May 94
Revance Therapeutics, Inc.0001209191-16-118599
SEC(opens sec.gov)
May 144
Revance Therapeutics, Inc.0001209191-15-043022
SEC(opens sec.gov)
Feb 114
Revance Therapeutics, Inc.0001209191-14-009043
SEC(opens sec.gov)

Companies

Address

C/O TECHNOLOGY PARTNERS 100 SHORELINE HWY, BLDG B, STE 282

MILL VALLEY, CA, 94941